(Q36138879)

English

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer (English)

1 reference

Europe PubMed Central

12 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Per Eystein Lønning

8

object named as

Lønning PE

1 reference

Europe PubMed Central

12 August 2017

Steinar Lundgren

5

object named as

Lundgren S

1 reference

Europe PubMed Central

12 August 2017

author name string

Geisler J

1

1 reference

Europe PubMed Central

12 August 2017

King N

2

1 reference

Europe PubMed Central

12 August 2017

Dowsett M

3

1 reference

Europe PubMed Central

12 August 2017

Ottestad L

4

1 reference

Europe PubMed Central

12 August 2017

Walton P

6

1 reference

Europe PubMed Central

12 August 2017

Kormeset PO

7

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

1 October 1996

1 reference

Europe PubMed Central

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

12 August 2017

74

1 reference

Europe PubMed Central

12 August 2017

8

1 reference

Europe PubMed Central

12 August 2017

1286-1291

1 reference

Europe PubMed Central

12 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1996.531

0 references

Aromatase inhibitor development for treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 October 2017

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Effects of aminoglutethimide on adrenal steroid secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Source of Estrogen Production in Postmenopausal Women1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Inhibition of aromatase with CGS 16949A in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

2 July 2018

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

23 September 2018

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2075919

23 September 2018

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS--I. Quantitation of estrogens after initial hydrolysis of conjugates

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8883419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1996.531

1 reference

Europe PubMed Central

12 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36138879&oldid=2008600586"